Bayesian Optimization for Personalized Dose-Finding Trials with Combination Therapies
Authors:
James Willard,
Shirin Golchi,
Erica E. M. Moodie,
Bruno Boulanger,
Bradley P. Carlin
Abstract:
Identification of optimal dose combinations in early phase dose-finding trials is challenging, due to the trade-off between precisely estimating the many parameters required to flexibly model the possibly non-monotonic dose-response surface, and the small sample sizes in early phase trials. This difficulty is even more pertinent in the context of personalized dose-finding, where patient characteri…
▽ More
Identification of optimal dose combinations in early phase dose-finding trials is challenging, due to the trade-off between precisely estimating the many parameters required to flexibly model the possibly non-monotonic dose-response surface, and the small sample sizes in early phase trials. This difficulty is even more pertinent in the context of personalized dose-finding, where patient characteristics are used to identify tailored optimal dose combinations. To overcome these challenges, we propose the use of Bayesian optimization for finding optimal dose combinations in standard ("one size fits all") and personalized multi-agent dose-finding trials. Bayesian optimization is a method for estimating the global optima of expensive-to-evaluate objective functions. The objective function is approximated by a surrogate model, commonly a Gaussian process, paired with a sequential design strategy to select the next point via an acquisition function. This work is motivated by an industry-sponsored problem, where focus is on optimizing a dual-agent therapy in a setting featuring minimal toxicity. To compare the performance of the standard and personalized methods under this setting, simulation studies are performed for a variety of scenarios. Our study concludes that taking a personalized approach is highly beneficial in the presence of heterogeneity.
△ Less
Submitted 11 February, 2024; v1 submitted 26 October, 2023;
originally announced October 2023.
Risk management for analytical methods: conciliating objectives of methods, validation phase and routine decision rules
Authors:
Myriam Maumy,
B. Boulanger,
W. Dewe,
A. Gilbert,
B. Govaerts
Abstract:
In the industries that involved either chemistry or biology, such as pharmaceutical industries, chemical industries or food industry, the analytical methods are the necessary eyes and hear of all the material produced or used. If the quality of an analytical method is doubtful, then the whole set of decision that will be based on those measures is questionable. For those reasons, being able to a…
▽ More
In the industries that involved either chemistry or biology, such as pharmaceutical industries, chemical industries or food industry, the analytical methods are the necessary eyes and hear of all the material produced or used. If the quality of an analytical method is doubtful, then the whole set of decision that will be based on those measures is questionable. For those reasons, being able to assess the quality of an analytical method is far more than a statistical challenge; it's a matter of ethic and good business practices. Many regulatory documents have been releases, primarily ICH and FDA documents in the pharmaceutical industry (FDA, 1995, 1997, 2001) to address that issue.
△ Less
Submitted 31 December, 2007;
originally announced January 2008.